deltatrials
Active Not Recruiting PHASE1 NCT00600496

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors

Sponsor: AstraZeneca

Conditions Breast Cancer Breast Neoplasms Colon Cancer Colon Neoplasms Colonic Cancer Kidney Cancer Lung Cancer Melanoma
Interventions AZD6244 Dacarbazine Docetaxel Erlotinib Temsirolimus
Updated 34 times since 2017 Last updated: Nov 12, 2025 Started: Dec 14, 2007 Primary completion: Aug 20, 2010 Completion: Dec 31, 2025

A PHASE1 clinical study on Breast Cancer and Breast Neoplasms, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 34 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

34 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

▶ Show 29 earlier versions

  1. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  7. Apr 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  9. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  11. Jan 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  12. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  13. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  14. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  15. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

  16. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  17. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  18. Apr 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  19. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  20. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  21. Jul 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  22. Apr 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  23. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  24. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  25. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  26. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  27. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1

  28. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  29. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Detroit, United States
  • • Houston, United States
  • • Nashville, United States
  • • Philadelphia, United States